EssilorLuxottica Shares Leap After 1Q North America Demand Held Firm
By Joshua Kirby
Shares in Ray-Ban maker EssilorLuxottica SA gained ground Friday after the group posted first-quarter sales showing resilient demand for its products in North America and a boost from China's reopening postpandemic.
At 0730 GMT, shares traded up 5.3% at EUR184.80.
The Franco-Italian eyewear giant made sales of 6.15 billion euros ($6.75 billion) in the first three months of the year, 8.6% higher than in the same period the previous year, adjusted for currency effects. Sales growth was highest in developing markets in Latin America and Asia-Pacific, at 12%. But arguably more notable was the 7% growth in North America, an acceleration from the previous quarter.
"North America is particularly reassuring, considering the muted mass-market environment," analysts at Bernstein said in a note following the print.
And the group, which also licenses eyewear from luxury brands like Chanel, Prada and Burberry, can look forward to further sales impetus from the integration of recently-acquired Dutch retailer GrandVision, Citi analysts said in their own note.
"We increasingly see upside risks to our more cautious view on near-term growth given the strong execution year-to-date," Citi said.
Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby
(END) Dow Jones Newswires
April 21, 2023 04:10 ET (08:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom